Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Targeted Molecular Therapy
DRUG
2 trials
Sponsors
Wake Forest University Health Sciences
, Northwestern University
Conditions
EGFR Activating Mutation
Gliosarcoma
Recurrent Glioblastoma
Recurrent Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer
Early Phase 1
NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
Completed
NCT03020017
Northwestern University
Gliosarcoma, Recurrent Glioblastoma
Start: 2017-05-25
End: 2020-08-19
Updated: 2022-08-26
Phase 2
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Terminated
NCT02949843
Wake Forest University Health Sciences
EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Start: 2017-03-10
End: 2021-01-12
Updated: 2024-06-28
Related Papers
Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to Bedside.
2022-03-23
12 citations
IMMU-53. STING-ING GLIOBLASTOMA WITH SPHERICAL NUCLEIC ACIDS
Neuro-Oncology
2021-11-02
4 citations
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.
2021-03-01
219 citations
DDIS-03. DEVELOPMENT OF A NOVEL CLASS OF cGAS AGONISTS TO TRIGGER STING PATHWAY-DEPENDENT INNATE IMMUNE RESPONSES AGAINST GLIOBLASTOMA
Neuro-Oncology
2019-11-01
1 citations
A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.
Journal of Clinical Oncology
2019-05-20
51 citations